CorMedix Therapeutics Announces Share Repurchase Program

Core Viewpoint - CorMedix Therapeutics has announced a share repurchase program authorizing the repurchase of up to $75 million of its outstanding common stock, effective through December 31, 2027 [1] Financial Position - The company has a strong balance sheet with approximately $150 million in cash and cash equivalents as of December 31, 2025, and 79.3 million common shares outstanding [2] - The share repurchase program is seen as a disciplined way to return value to shareholders while maintaining financial flexibility for business investments [2] Share Repurchase Program Details - Repurchases may occur at management's discretion through various methods, including privately negotiated transactions, block trades, and open market purchases [3] - The program is subject to market conditions, liquidity, cash flow considerations, and applicable securities laws [3] - There is no obligation for CorMedix to repurchase any specific amount of shares, and the program may be suspended or discontinued at any time [3] Company Overview - CorMedix is focused on developing and commercializing therapeutic products for life-threatening conditions, including the commercialization of DefenCath for preventing catheter-related bloodstream infections [4] - Following the acquisition of Melinta Therapeutics LLC in August 2025, CorMedix is also commercializing a portfolio of anti-infective products [4] Clinical Development - CorMedix has ongoing clinical studies for DefenCath in Total Parenteral Nutrition and Pediatric Hemodialysis populations, with plans to develop it as a catheter lock solution for other patient populations [5] - REZZAYO is approved for treating candidemia and invasive candidiasis in adults, with a Phase III study ongoing for prophylaxis of invasive fungal disease in adult patients undergoing allogeneic bone marrow transplantation, with topline results expected in Q2 2026 [5]